HDM1005 1
Phase 3Small molecule
HDM1005 1 is one of 82 small molecule programs targeting Overweight. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
171 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1HDM1005 1
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Routine Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metformin2 trials
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT07417306·912 enrolled
Overweight1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HDM1005 1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details